Literature DB >> 1899624

Treatment of pure red cell aplasia after major ABO-incompatible bone marrow transplantation with recombinant erythropoietin.

A Heyll, C Aul, V Runde, M Arning, W Schneider, P Wernet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1899624

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  3 in total

Review 1.  Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question.

Authors:  Javier Marco-Ayala; Inés Gómez-Seguí; Guillermo Sanz; Pilar Solves
Journal:  Bone Marrow Transplant       Date:  2020-11-14       Impact factor: 5.483

2.  Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins.

Authors:  Georg Stussi; Jörg Halter; Eveline Bucheli; Piero V Valli; Lutz Seebach; Jürg Gmür; Alois Gratwohl; Urs Schanz; Jakob R Passweg; Jörg D Seebach
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

3.  Successful Treatment of Pure Red Cell Aplasia with Rituximab in Patients after ABO-Compatible Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Sung-Hoon Jung; Jae-Sook Ahn; Deok-Hwan Yang; Hyung Chul Park; Soo-Young Bae; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Case Rep Oncol       Date:  2012-02-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.